Drug intelligence / Profile preview

Chixiangshen Tongxin

Development stage: Phase 4
Lead developer: Liaoning University of Traditional Chinese Medicine
Administration: Oral

Overview

Chixiangshen Tongxin is a Traditional Chinese Medicine (TCM) granule formulation developed by the Liaoning University of Traditional Chinese Medicine for the treatment of stable angina pectoris in patients with coronary heart disease. The therapy is designed based on TCM theories of replenishing Qi and activating blood circulation to resolve stasis. It is typically evaluated as an adjunctive therapy to standard Western treatments. Clinical research, including Phase 4 trials, has focused on establishing standardized efficacy evaluation systems for TCM in cardiovascular health, utilizing patient-reported outcomes and clinical indicators.

Other names: Chixiangshen Tongxin granules

Beyond the preview

Go deeper on Chixiangshen Tongxin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Chixiangshen Tongxin.

Explore the full profile